(Gene Therapy)
Dr. Debaditya Bhattacharya, Vice President of CMC Technical Development and External Manufacturing, joined Myrtelle in 2025 bringing over 14 years of Biotech experience in product development of cell and gene therapies and complex biologics.
Most recently, Deb was the Vice President of Analytical Development at Elevatebio where he led the analytical development, tech transfer strategy, and testing operations focusing on gene and cell therapy drug products, lentiviral vector and AAV, and other modalities. Prior to Elevatebio, Deb has held various roles of increasing responsibility at CRISPR Therapeutics, bluebird bio, and Aura Biosciences. Through his professional journey, Deb has led CMC teams and contributed towards the progression of CRISPR-editing based immuno-oncology cell therapy products, ex vivo CAR T therapies for treatment of cancer and autoimmune diseases, hematopoietic stem cell therapies and in vivo gene therapies for treatment of genetic disorders, and virus-like drug conjugate for treating a rare form of cancer.
Deb is experienced in progressing drug development projects from early pre-clinical stages, through different phases of clinical and late-stage development and has contributed to several regulatory submissions including two marketing applications.
Deb earned his Ph.D. in Molecular Microbiology from Tufts University Boston. He completed his M.Tech. in Biotechnology from GGS Indraprastha University Delhi, India, during which he was awarded the University Gold medal for academic excellence.
Outside of work, Deb has special interest in cooking, traveling, cricket, and board games, all of which he enjoys while spending time with family and friends.
(Gene Therapy)
(Canavan Disease)